Consumer blood testing

Consumer blood testing is the sale of clinical laboratory panels directly to people who have no symptoms and no physician's referral, marketed as preventive or proactive medicine. The assays themselves are ordinary hospital chemistry, run in certified laboratories, and mostly accurate. What is contested is the inference drawn from them: whether measuring dozens or hundreds of analytes in a person who feels well yields information that makes them healthier, or mainly yields abnormal-looking numbers.

§What is sold

The transaction is uniform across sellers. A consumer orders a panel online; a contracted physician network signs the requisition where state law still requires a clinician's order; blood is drawn at a commercial service centre, by a mobile phlebotomist, or through a mail-in capillary kit. Results arrive in an application rather than a consultation, colour-coded against a range and accompanied by generated advice on diet, Dietary supplements, sleep and training.

Quest and Labcorp, the dominant American reference laboratories, sell consumer-initiated versions of the tests they run for hospitals. Everlywell built its business on mail-in kits aimed at single questions; InsideTracker pairs a modest panel with algorithmic nutrition advice; Function Health, co-founded by the physician and author Mark Hyman, sells an annual membership covering on the order of a hundred biomarkers. The category has extended into whole-body MRI screening sold on comparable terms by companies such as Prenuvo.

Panels routinely include analytes with no established screening indication in healthy adults: vitamin D, extended thyroid batteries, high-sensitivity C-reactive protein sold as a readout of Inflammaging, ferritin, sex-hormone panels, and add-ons for telomere length or methylation age. Many sellers report results against a proprietary "optimal" band narrower than the laboratory's own reference interval, which mechanically increases the share of results flagged as actionable.

What certification covers

A CLIA-certified laboratory has demonstrated that it measures what it claims to measure, to a stated precision, under audit. Certification says nothing about whether the test should have been ordered. Consumer marketing routinely answers the accuracy question while appearing to answer the utility one.

§Development history

1. 2013–2014
   Theranos enters retail
   Theranos opens wellness centres inside Walgreens stores, first in California and then across the Phoenix area, promising a full laboratory panel from a fingerstick sample.
2. 2015
   Direct-access testing broadens
   Arizona enacts a law, lobbied for by Theranos, letting residents order any laboratory test without a physician's order; a Wall Street Journal investigation later that year reports that the company runs only a small fraction of the tests it offers on its own device.
3. 2016
   Regulators act
   The US agency that certifies clinical laboratories revokes the certificate of Theranos's California facility and bars Elizabeth Holmes from operating a lab for two years. The company voids or corrects large numbers of previously reported results.
4. 2019–2021
   Reference labs go direct
   Quest and Labcorp launch consumer-facing platforms selling much of their own catalogue without a physician visit.
5. 2020
   The pandemic normalizes home collection
   Emergency authorizations for at-home sample collection, including one granted to Everlywell, make mail-in specimen kits a familiar consumer product.
6. 2022
   Fraud conviction
   Holmes is convicted in January on four counts of defrauding investors, acquitted on the counts relating to patients, and sentenced later that year to more than eleven years.
7. 2023–2026
   Longevity-branded panels
   Membership services selling a hundred or more analytes a year, framed around biological aging rather than disease, become a prominent part of the market.

Theranos is the field's cautionary anchor, and it is routinely misremembered. The fraud lay not in selling consumers their own laboratory data but in the specific, false claim that a full panel could be run from a few drops of capillary blood on a proprietary device.¹ Most samples the company processed went to conventional commercial analysers. The demand it identified outlived it, which is why the same retail model returned within a few years under companies making no device claims at all.

§The arithmetic of reference ranges

The central scientific objection to broad panels is not about assay quality. A reference interval describes a population; it is not a boundary between health and disease. By convention a laboratory sets it to cover the central 95 percent of a defined healthy reference group,² so roughly one result in twenty from a person with nothing wrong falls outside it by construction.

Test many analytes at once and the flags accumulate. On twenty statistically independent tests the probability that a completely healthy person has at least one out-of-range value is about 64 percent; on a hundred, an all-normal report is the unusual outcome. Real analytes are correlated, so the true figure is lower than the naive calculation, but the direction is not in doubt. A panel wide enough to be marketed as comprehensive is wide enough that most healthy customers will see something flagged.

Intervals carry a second problem: each is drawn from whichever population a laboratory sampled on whichever platform it ran, so the same blood can be flagged by one laboratory and normal in another.

§What screening evidence supports

Bodies that evaluate screening do so one test at a time, against evidence that finding the condition early changes an outcome. The US Preventive Services Task Force grades each proposed test on that basis and issues an "insufficient evidence" statement where the evidence does not settle whether testing helps or harms, as it has for vitamin D screening in asymptomatic adults.³ No screening body recommends broad multi-analyte panels in people without symptoms, and the professional-society Choosing Wisely lists target several of the tests such panels sell most heavily.

The closest direct test of the strategy is the trial literature on periodic general health checks, which bundled bloodwork with examination. A Cochrane review of those randomized trials found no effect on all-cause, cardiovascular or cancer mortality while documenting increases in diagnoses and in treatment.⁴ That is a result about a programme rather than about any single analyte, and it remains the nearest evidence to the claim consumer testing makes.

Population range or personal baseline

The strongest case for repeat testing is not the cross-sectional flag but the within-person trend: an individual varies around their own set point within a band narrower than the population interval, so a real drift can be visible while every value stays technically normal. Personal reference intervals are a long-standing idea in laboratory medicine, and the same argument underpins Continuous glucose monitoring and Wearable health sensors. Missing is any trial showing that acting on such trends improves outcomes in healthy people.

§Multi-cancer early detection

A distinct and more consequential category shares the same retail channel. Multi-cancer early detection tests, of which Galleri is the most prominent, look for tumour-derived DNA fragments and methylation signatures in blood, reporting a cancer signal and a predicted tissue of origin. As laboratory-developed tests they have fallen outside routine premarket review; a 2024 US rule that would have changed that was vacated by a federal district court the following year.⁵

The performance data are genuinely interesting and genuinely insufficient. In a published prospective study of Galleri in adults aged 50 and older, fewer than half of the participants with a positive signal proved to have cancer, and resolution took months of imaging and procedures for many of them.⁶ A large randomized trial in England enrolled on the order of 140,000 participants and was designed around a reduction in late-stage diagnoses rather than deaths. As of mid-2026 no multi-cancer test is recommended for routine screening by a national body, and none has been shown to reduce cancer mortality.

A different risk profile

A false positive on a cholesterol panel costs a repeat draw. A false positive on a multi-cancer test can commit a well person to imaging, endoscopy and biopsy while the signal's source is hunted, and a true positive for a cancer that would never have caused symptoms commits them to treatment for it. Both the potential benefit and the potential harm are larger than for ordinary panels, and the harms are at present the better characterised of the two.

§Harms and the diagnostic cascade

Overdiagnosis is the organising concept. Screening a healthy population finds indolent disease that would never have surfaced, and because the person is then treated, every such case enters the statistics as a life saved. Thyroid cancer in South Korea is the clearest documented case: incidence rose roughly fifteenfold as ultrasound screening spread, with essentially no change in mortality from the disease.⁷ That is an argument for grading each test against outcomes rather than against detection, not against screening as such.

The proximate harm from a flagged panel is the cascade. An out-of-range value invites a confirmatory test, then imaging, then an incidental finding on that imaging, then a procedure — a sequence in which each step is locally reasonable and the endpoint was not warranted by the starting point. Diagnostic labels also carry an effect independent of treatment, documented since a 1978 study found absenteeism rose among steelworkers after they were told they were hypertensive.⁸

The reversibility of the technology is unusual here. The draw leaves nothing behind and testing can simply be stopped; a result cannot be un-known, and the workup it sets off can end in a biopsy, a diagnosis, or a permanent notation that no later normal test removes.

Two structural harms round out the list. Companies that do not bill insurers may sit outside the health-privacy rules governing clinical records, accumulating longitudinal biological data under consumer-software terms, which connects the practice to Genetic discrimination and Mental privacy. And because the panels are paid out of pocket, they route clinician attention toward people who can afford them, an inversion of need familiar from Access and inequality.

§Outlook

Consumer testing is embedded in longevity practice, where panels serve as the entry point to Biohacking and grinders self-experimentation, to off-label prescribing of drugs such as Metformin and the TAME trial and GLP-1 receptor agonists, and to composite biological age scores whose underlying biomarker validity is unresolved.

Three developments would change the assessment. The first is randomized evaluation of the strategy rather than the assay: whether people given a broad panel end up healthier than people not given one. The second is a shift from population intervals to individual baselines with published reliability, which would make repeat testing statistically defensible and is where integrated personal modelling points. The third is triage that reduces rather than multiplies downstream procedures, the promise attached to nanoscale assays.

Until then the field faces an uncomfortable comparison. The actions most reliably recommended after a consumer panel — structured exercise, sleep, weight, alcohol, smoking — are the ones recommended without it, and the Healthspan case built on the Geroscience hypothesis does not obviously require a hundred analytes to make. A test that changes what someone does is worth its cost. Most of these have not been shown to.

§See also

• Aging biomarkers
• Biological age
• Epigenetic clocks
• Quantified self
• Wearable health sensors
• Biohacking and grinders
• Access and inequality
• Compression of morbidity

§References